Wells Fargo raised the firm’s price target on Cardinal Health (CAH) to $185 from $183 and keeps an Overweight rating on the shares. The firm updates its model following Q4 2025 earnings and increases its estimates for Other/core pharma distribution growth.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health’s Growth Potential: Buy Rating Reaffirmed Amid Strong Pharma Performance and Strategic Focus
- Cardinal Health Reports Strong Q4 and FY 2025 Results
- Cardinal Health: Strategic Acquisitions and Raised Guidance Justify Buy Rating
- Cardinal Health’s Strong Performance and Strategic Initiatives Justify Buy Rating
- Cardinal Health price target lowered to $186 from $188 at Leerink